FIELD: medicine. SUBSTANCE: method involves studying biological fluids for determining concentration of monomeric and homodimeric types of osteoclastogenesis-inhibiting factor (OCIF) in the biological fluid samples by means of monoclonal antibodies equally effective in recognizing both monomer and homodimeric types of OCIF and having dissociation constant less than 10-9 M with antigen or selectively recognizing dimeric OCIF type and having dissociation constant less than 2•10-7 M with antigen. A monoclonal antibody is claimed that is capable of equally effectively recognizing both monomer and homodimeric types of OCIF, as well as monoclonal antibody capable of selectively recognizing dimeric OCIF type and a set containing the above mentioned antibodies. EFFECT: high specificity and accuracy of measurements and diagnosis. 15 cl, 6 dwg, 1 tbl
Title |
Year |
Author |
Number |
COMPLEX COMPRISING OSTEOCLASTOGENESIS-INHIBITORY FACTOR (OCIF) AND POLYSACCHARIDE |
2002 |
- Jamamoto Siniti
- Okada Dzuniti
- Kurikhara Atsusi
- Numazava Taku
- Kondo Dzuniti
- Tsuda Eisuke
- Motizuki Siniti
- Nisi Khirotaka
- Mijazaki Khideki
|
RU2232594C2 |
ANTIBODY DIRECTED ON SIGLEC-15 PROTEIN, BOUND WITH OSTEOCLASTS |
2008 |
- Khiruma Josikharu
- Tsuda Ejsuke
|
RU2475499C2 |
NOVEL PROTEINS AND METHODS OF THEIR PREPARING |
1996 |
- Goto Masaaki
- Tsuda Ehjsuke
- Motizuki Siniti
- Jano Kazuki
- Kobajasi Fumie
- Sima Nobujuki
- Jasuda Khisataka
- Nakagava Nobuaki
- Morinaga Tomonori
- Ueda Masatsugu
- Khigasio Kandzi
|
RU2194714C2 |
PROTEIN ABLE TO INHIBIT OSTEOCLASTOGENESIS (OCIF) (VARIANTS), CDNA, METHOD FOR PREPARING PROTEIN, METHOD FOR TREATMENT OF OSTEOPOROSIS, METHOD FOR TREATMENT AND/OR IMPROVEMENT OF BONE MASS RECOVERY, METHOD FOR TREATMENT OF INJURE ASSOCIATED WITH OSSEOUS METABOLISM, TRANSFORMED STRAIN ESCHERICHIA COLI PBK/01F10 AND PHARMACEUTICAL COMPOSITION |
1996 |
- Goto Masaaki
- Tsuda Ehjsuke
- Motizuki Siniti
- Jano Kazuki
- Kobajasi Fumie
- Sima Nobujuki
- Jasuda Khisataka
- Nakagava Nobuaki
- Morinaga Tomonori
- Ueda Masatsugu
- Khigasio Kandzi
|
RU2238948C2 |
Siglec-15 ANTIBODY |
2010 |
- Khiruma Josikharu
- Tsuda Ejsuke
- Takizava Takesi
- Nakajama Makiko
|
RU2539790C2 |
PROTEIN BINDING SPECIFICALLY WITH OSTEOCLASTOGENESIS-INHIBITING FACTOR (OCIF) (VARIANTS), DNA ENCODING ITS (VARIANTS), DNA AS PROBE (VARIANTS), METHOD FOR PREPARING PROTEIN (VARIANTS), METHOD FOR SCREENING SUBSTANCE (VARIANTS), ANTIBODY (VARIANTS), METHOD FOR PREPARING POLYCLONAL ANTIBODY, HYBRIDOMA (VARIANTS), METHOD FOR PREPARING MONOCLONAL ANTIBODY, METHOD FOR ASSAY OF OCIF-BINDING PROTEIN, PHARMACEUTICAL COMPOSITION (VARIANTS) AND MEDICINAL AGENT (VARIANTS) |
1998 |
- Jamaguti Kiodzi
- Jasuda Khisataka
- Nakagava Nobuaki
- Sima Nobujuki
- Kinosaki Masakhiko
- Tsuda Eisuke
- Goto Masaaki
- Jano Kazuki
- Tomojasu Akikhiro
- Kobajasi Fumie
- Vasida Naokhiro
- Takakhasi Ken
- Morinaga Tomonori
- Khigasio Kandzi
|
RU2238949C2 |
POLYNUCLEOTIDE SEQUENCE (VARIANTS), POLYPEPTIDE (VARIANTS), FUSED PROTEIN, PHARMACEUTICAL COMPOSITION, MONOCLONAL ANTIBODY, STRAIN OF HYBRID CULTURED CELLS |
1995 |
- Tokhru Takakhasi
- Rjuta Koisi
- Itiro Kavasima
- Nobufuza Serizava
|
RU2143491C1 |
ANTIBODY AGAINST TUMOR-SPECIFIC ANTIGENS AS TARGET |
2004 |
- Itikava Kimikhisa
- Takakhasi Su
- Agatsuma Tosinori
- Fukuti Kejsuke
- Khirai Takekhiro
|
RU2345090C2 |
POLYMERIC MODIFYING AGENTS AND PHARMACEUTICAL COMPOSITIONS |
2004 |
- Kasuja Judzi
- Khonma Masasi
|
RU2323227C2 |
ANTI-ROBO4 ANTIBODY |
2013 |
- Isumi Joshitaka
- Sato Toshiyuki
- Khasegava Dzhun
- Inoue Tatsuya
|
RU2682451C2 |